^
    3d
    Discovery of novel 2,4-diarylaminopyrimidine derivatives as FAK inhibitors with potent anti-cancer potency. (PubMed, Future Med Chem)
    A series of derivatives (D1-D15) was designed and synthesized by incorporating a hydrazone unit into the TAE-226 scaffold...Mechanistically, compound D12 effectively suppressed FAK phosphorylation and downstream MAPK/ERK and AKT/mTOR signaling, leading to inhibition of colony formation, migration, cell cycle progression, and induction of apoptosis. Compound D12 is a novel FAK inhibitor with improved selectivity and potent antitumor activity, representing a promising lead candidate for cancer therapy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    NVP-TAE226
    5d
    MHB018A Treatment in Patients With Active Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=108, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Trial completion date: Jul 2028 --> Jul 2027 | Trial primary completion date: Jan 2027 --> Jul 2026
    Trial completion date • Trial primary completion date
    6d
    Construction of a novel risk model for esophageal squamous cell carcinoma associated with purinergic signaling pathways and chemoradiotherapy sensitivity genes. (PubMed, Front Med (Lausanne))
    Drugs like VX.702 and BMS.754807 were more effective in the high-risk group...ESCC tumor tissues exhibited markedly decreased AMN and ERICH5 expression but increased HRG compared to normal controls. This study identified prognostic signature genes associated with CRT and PS in ESCC and constructed a risk model that may predict patient survival, which could provide valuable insights for future research on ESCC diagnosis and treatment.
    Journal
    |
    ANXA10 (Annexin A10)
    |
    BMS-754807
    8d
    Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=258, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Jan 2029
    Enrollment open • Trial completion date • Trial primary completion date
    8d
    MHB018A-P-302: MHB018A Treatment in Patients With Chronic Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=150, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Aug 2028 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Aug 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    14d
    Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a case report. (PubMed, Front Oncol)
    We present a patient with Anaplastic lymphoma kinase (ALK) fusion lung adenocarcinoma who received sequential treatment with ALK tyrosine kinase inhibitor (TKI) (crizotinib, PFS:32.3 months and then conteltinib, PFS: 29 months). Subsequently, the patient switched to third generation EGFR-TKI treatment with almonertinib. This case suggests EGFR mutation is one of the mechanisms of ALK-TKI resistance, highlights the value of re-biopsy in identifying potentially targetable resistance mechanisms and underscores the spatiotemporal heterogeneity of tumors under the selective pressure of ALK-TKI.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • ALK fusion • ALK mutation
    |
    Xalkori (crizotinib) • Ameile (aumolertinib) • conteltinib (SY-707)
    14d
    A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy (clinicaltrials.gov)
    P3, N=53, Completed, Peking University People's Hospital | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Jul 2025
    Trial completion • Trial completion date
    22d
    Dual targeting of IGF-1R and K-RAS with natural phytochemicals for lung cancer therapy: an in-silico study. (PubMed, J Genet Eng Biotechnol)
    According to the results, 17Beta-Hydroxywithanolide K and Ginkgolide A demonstrated strong binding affinity to IGF-1R (-9.4 Kcal/mol) and KRAS (-6.9 Kcal/mol), respectively, compared to the synthetic inhibitors Picropodophyllin (-7.7 Kcal/mol) and Sotorasib (-5.9 Kcal/mol). Overall, 17Beta-Hydroxywithanolide K and Ginkgolide A have potential as natural therapeutic agents for the treatment of lung cancer. However, additional in vitro and in vivo experiments are needed to validate these computational results.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Lumakras (sotorasib) • picropodophyllin (AXL1717)
    1m
    HAZEL 401: An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Amgen
    New P2 trial
    2ms
    Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Peking University Third Hospital
    New trial
    |
    Tepezza (teprotumumab-trbw)
    2ms
    Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    everolimus • temozolomide • doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • irinotecan • temsirolimus • vincristine • daunorubicin • ganitumab (AMG 479)
    2ms
    20230302: A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye Disease (2024-514110-12-00)
    P1/2, N=19, Recruiting, Amgen Inc.
    New P1/2 trial